LINC01194 and prostate carcinoma: It has been identified as a tumor antigen, and as a potential therapeutic target for cervical and ovarian cancer [38, 39], multiple myeloma [41], breast cancer [42], prostate cancers [43] and importantly for NSCLCs [40].